Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies

By Tae‐You Kim, Dong-Wan Kim, J. Chung, Sang‐Goo Shin, Sung-chul Kim, D. Heo, Noe K. Kim, Y. Bang. Clinical Cancer Research, 2004

734 citations recorded by the source corpus.

Subfields: Biomaterials, Oncology

View Paper: https://www.semanticscholar.org/paper/b3fa967fa94e55d8b80462ff49a7625db893111a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Oncology

Citations in the corpus

Cancer nanomedicine: a review of recent success in drug delivery (2017, background): “South Korea (2007) Genexol‐PM PEG‐PLA polymeric micelle Paclitaxel 20–50 nm [85] Breast cancer, Lung cancer, Ovarian cancer [126]”
Shape effects of filaments versus spherical particles in flow and drug delivery. (2007, background): “, as are a broad array of drug-laden, polymer-based spherical micelle”
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery (2006, background): “Again, the conclusion was that Genexol-PM was superior to conventional paclitaxel in terms of the obviation of premedication and the delivery of higher paclitaxel doses without additional toxicity (48).”
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release (2010, background): “In phase I studies, a MTD 390 mg/m(2) every 3 weeks or 120 mg/m(2) every week was determined without the occurrence of hypersensitivity reactions (28,51).”
Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “…as simple aqueous solutions but may also be freeze-dried to form solid inclusion complexes (Brewster et al., 1991; Xiang and Anderson, 2002; Lockwood et al., 2003; Hong et al., 2011) that are reconstituted with water or saline immediately before administration (Kim et al., 2004a; Strickley, 2004).”
Microtubule-binding agents: a dynamic field of cancer therapeutics (2010, background): “Several novel generic formulations of paclitaxel and docetaxel aim to eliminate surfactants from current formulations, which may eventually lead to reduced hypersensitivity reaction”
Role of nanotechnology in targeted drug delivery and imaging: a concise review. (2005, methodology): “Finally, nanocarriers composed of biocompatible materials [13-16] are investigated as safe alternatives to existing vehicles, such as CremophorR EL (BASF, Mount Olive, NJ), that may cause hypersensitivity reactions and peripheral neuropathy [17,18].”